Screener / SEC EDGAR /CIK 0001384101 /10-K filed Feb 26, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Medical Labs

Veracyte, Inc. VCYT

At Veracyte, we believe that exceptional cancer care begins with exceptional diagnostics. 10-K, Item 1

Headquarters
South San Francisco, CA
CEO
Marc Stapley
Next results
around Jan 11, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $517.1M through the costs to a net profit of $66.4M · income statement of the 10-K

11% operating margin
Revenue to Gross profit: $362.5MRevenue to Cost of revenue: $154.6MGross profit to Operating profit: $57.8MGross profit to Operating expenses: $304.8MOperating profit to Net profit: $55.9MOperating profit to Tax: $1.8MOther income to Net profit: $10.4MOperating expenses to R&D: $70.8MOperating expenses to Sales, admin & other: $233.9M Revenue: $517.1M REVENUE $517.1M +16% Y/Y Gross profit: $362.5M · 70% margin GROSS PROFIT $362.5M 70% margin · +22% Y/Y Cost of revenue: $154.6M · 30% of revenue COST OF REVENUE $154.6M 30% of revenue Operating profit: $57.8M · 11% margin OPERATING PROFIT $57.8M 11% margin · +258% Y/Y Other income: $10.4M · 2% of revenue OTHER INCOME $10.4M 2% of revenue Operating expenses: $304.8M · 59% of revenue OPERATING EXPENSES $304.8M 59% of revenue Net profit: $66.4M · 13% margin NET PROFIT $66.4M 13% margin · +175% Y/Y Tax: $1.8M · 0% of revenue TAX $1.8M 0% of revenue R&D: $70.8M · 14% of revenue R&D $70.8M 14% of revenue Sales, admin & other: $233.9M · 45% of revenue SALES, ADMIN & OTHER $233.9M 45% of revenue
Gross profit $362.5M 70% margin · +22% Y/Y
Operating profit $57.8M 11% margin · +258% Y/Y
Net profit $66.4M 13% margin · +175% Y/Y
The full income statement, year by year

VCYT among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 16.0%, above 66% of 154 peers (their median 10.4%) REVENUE GROWTH 16.0% · above 66% Gross margin: 72.0%, above 73% of 107 peers (their median 63.4%) GROSS MARGIN 72.0% · above 73% Operating margin: 17.1%, above 71% of 138 peers (their median 9.8%) OPERATING MARGIN 17.1% · above 71% Net margin: 21.8%, above 86% of 153 peers (their median 6.7%) NET MARGIN 21.8% · above 86% FCF margin: 27.8%, above 92% of 144 peers (their median 9.9%) FCF MARGIN 27.8% · above 92% Return on capital: 3.9%, above 13% of 89 peers (their median 9.2%) RETURN ON CAPITAL 3.9% · above 13%
VCYT Peer median Below the median

What changed

11 new risk paragraphs. 10-K filed Feb 26, 2026 against Feb 28, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 11 checks found nothing to note

  • Receivables -4.0% ($46.5M to $44.7M) vs revenue +16.0% ($445.8M to $517.1M), -20.0 pts apart
  • Cash from operations $136.3M vs net income $66.4M (FY ending Dec 31, 2025)
  • Inventory -5.5% ($21.8M to $20.5M) vs revenue +16.0% ($445.8M to $517.1M), -21.5 pts apart
8 more checks with nothing to note
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Revenue from testing
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

11 paragraphs in Risk Factors that were not in the 10-K filed Feb 28, 2025. Quoted as filed.

All 11 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    IVDR’s transitional timelines regarding compliance deadlines according to IVD risk classifications as well as designations of Swiss Authorized Representatives.
  2. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    Furthermore, the C2i Acquisition included acquiring personal data that may originate from, be processed in, or be transferred to and from, Israel, the EU and other jurisdictions. Our ability to process, use and transfer such personal data may

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$296.5M$361.1M$445.8M$517.1M
Net income−$36.6M−$74.4M$24.1M$66.4M
Operating cash flow$7.5M$44.2M$75.1M$136.3M
Free cash flow−$1.0M$34.3M$63.8M$126.6M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$517.1M ▲ 16.0% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

5 filings in the last 30 days · SEC EDGAR

All filings

About the company

Veracyte, Inc., South San Francisco, CA · from the 10-K filed Feb 26, 2026

At Veracyte, we believe that exceptional cancer care begins with exceptional diagnostics. We are a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic and predictive treatment decisions. Insights from these tests help patients avoid unnecessary procedures and interventions and accelerate time to appropriate treatment, thereby improving outcomes for patients across our global markets.

Headquarters
South San Francisco, CA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 4, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Feb 28, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/VCYT/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.